Advertisement

Advertisement

CABA Stock Latest News

Morgan Stanley and Jefferies Analysts Forecast Over 350% Upside Potential for Cabaletta Bio Stock

Market NewsMorgan Stanley and Jefferies Analysts Forecast Over 350% Upside Potential for Cabaletta Bio Stock

Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley

PremiumThe Fly

Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley

19d ago

Cabaletta Bio price target raised to $16 from $15 at Guggenheim

PremiumThe Fly

Cabaletta Bio price target raised to $16 from $15 at Guggenheim

19d ago

Midday Fly By: Musk to start Terafab project, Elliott takes stake in Synopsys

PremiumThe Fly

Midday Fly By: Musk to start Terafab project, Elliott takes stake in Synopsys

20d ago

Cabaletta Bio Updates Rese-cel Programs and Financial Outlook

PremiumCompany Announcements

Cabaletta Bio Updates Rese-cel Programs and Financial Outlook

20d ago

Cabaletta Bio reports Q4 EPS (40c), consensus (47c)

PremiumThe FlyCabaletta Bio reports Q4 EPS (40c), consensus (47c)

20d ago

Cabaletta Bio, Inc. (CABA) Q4 Earnings Cheat Sheet

Pre-Earnings

Cabaletta Bio, Inc. (CABA) Q4 Earnings Cheat Sheet

1M ago

Cabaletta Bio participates in a conference call with William Blair

The Fly

Cabaletta Bio participates in a conference call with William Blair

2M ago

Largest borrow rate increases among liquid names

PremiumThe Fly

Largest borrow rate increases among liquid names

2M ago

Dave & Buster’s, American Eagle, Cabaletta, Abeona, Oncolytics Insider Shock

PremiumWeekend Updates

Dave & Buster’s, American Eagle, Cabaletta, Abeona, Oncolytics Insider Shock

3M ago

Cabaletta Bio: Advancing Rese-cel Across Autoimmune Indications with Streamlined Registrational Strategies and 2026 Value Catalysts Supporting Buy Rating

PremiumRatings

Cabaletta Bio: Advancing Rese-cel Across Autoimmune Indications with Streamlined Registrational Strategies and 2026 Value Catalysts Supporting Buy Rating

3M ago

Cabaletta Bio Sets 2026 Strategy for Rese-cel Expansion

PremiumCompany Announcements

Cabaletta Bio Sets 2026 Strategy for Rese-cel Expansion

3M ago

Cabaletta Bio announces 2026 strategic priorities

PremiumThe FlyCabaletta Bio announces 2026 strategic priorities

3M ago

Cabaletta Bio price target lowered to $14 from $22 at Morgan Stanley

The Fly

Cabaletta Bio price target lowered to $14 from $22 at Morgan Stanley

3M ago

Cabaletta Bio’s treatment of myasthenia gravis granted FDA orphan designation

The Fly

Cabaletta Bio’s treatment of myasthenia gravis granted FDA orphan designation

4M ago

Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating

PremiumRatings

Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating

5M ago

Cabaletta Bio Advances in Autoimmune Therapy Development

PremiumCompany Announcements

Cabaletta Bio Advances in Autoimmune Therapy Development

5M ago

Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating

PremiumRatings

Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating

5M ago

Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

PremiumRatings

Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

5M ago

Cabaletta Bio reports Q3 EPS (44c), consensus (46c)

PremiumThe FlyCabaletta Bio reports Q3 EPS (44c), consensus (46c)

5M ago

Cabaletta Bio sees cash runway into 2H26

The Fly

Cabaletta Bio sees cash runway into 2H26

5M ago

Is CABA a Buy, Before Earnings?

Pre-Earnings

Is CABA a Buy, Before Earnings?

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >